Enthera SRL

Enthera SRL is a privately held Italian biotechnology company headquartered in Milan, Italy. Founded in 2016, the company is focused on developing first-in-class biologics for severe autoimmune disorders, with an initial emphasis on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). Enthera's therapeutic strategy is built around a novel biological pathway—the IGFBP3/TMEM219 axis—which is involved in cell apoptosis in the gut, pancreas, and other organs. By targeting this pathway, the company aims to preserve and re-establish organ cell function, offering a disease-modifying approach rather than merely managing symptoms. The company's proprietary discovery engine generates libraries of monoclonal antibodies (mAbs) and fusion proteins that selectively inhibit the binding of IGFBP3 to the TMEM219 receptor. This approach is designed to protect endogenous stem cells and restore organ function in conditions where current treatments are limited and often fail. Enthera's lead clinical candidate, Ent001, is described as the only drug in development with the potential to preserve and restore the endogenous pancreatic beta cell compartment in T1D and the original intestine structure in IBD. Enthera operates as a private company and is engaged in in-house development of its pipeline. Its corporate headquarters are located at Via Borgogna, 5, 20122 Milan, while its registered office is at Via Visconti di Modrone Uberto, 18, 20122 Milan. The company maintains a lean organizational structure, with key personnel including Giovanni Ravaioli as People and Organization Advisor and Piera Caterina Viscardi as Accountant. Paolo Fiorina serves as Chief Scientific Officer. Enthera's website emphasizes its commitment to addressing underserved autoimmune conditions with high unmet medical need, and it actively seeks investment opportunities to advance its clinical programs.

Enthera SRL was founded in 2016 in Milan, Italy, as a privately held biotechnology company. The company emerged from a breakthrough discovery related to the IGFBP3/TMEM219 pathway, a novel biological mechanism involved in stem cell apoptosis and the development of autoimmune conditions. From its inception, Enthera has focused on translating this discovery into first-in-class biologic therapeutics for severe autoimmune disorders with high unmet medical need. The company's scientific foundation rests on targeting the IGFBP3/TMEM219 axis, which plays a key role in the apoptosis of stem cells in the gut, pancreas, and other organs. This pathway is implicated in the pathogenesis of Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). Enthera's approach aims to preserve and re-establish organ cell function by inhibiting the binding of IGFBP3 to the TMEM219 receptor, thereby protecting endogenous stem cells and potentially modifying the course of disease. Enthera has developed a proprietary discovery engine that generates libraries of monoclonal antibodies (mAbs) and fusion proteins targeting the IGFBP3/TMEM219 pathway. These selective inhibitors are designed to abrogate the binding capability of IGFBP3 to TMEM219 using multiple approaches at different stages of the pathway. The company's pipeline includes Ent001, its lead clinical candidate, which is described as the only drug in development with the potential to preserve and restore the endogenous pancreatic beta cell compartment in T1D and the original intestine structure in IBD. As a private company, Enthera has pursued in-house development of its clinical candidates. The company maintains a corporate headquarters at Via Borgogna, 5, 20122 Milan, and a registered office at Via Visconti di Modrone Uberto, 18, 20122 Milan. Its team includes Paolo Fiorina as Chief Scientific Officer, Giovanni Ravaioli as People and Organization Advisor, and Piera Caterina Viscardi as Accountant. Enthera continues to seek investment opportunities to advance its mission of developing disease-modifying treatments for intractable autoimmune diseases.

• 2016

  Enthera SRL founded in Milan, Italy, as a privately held biotechnology company.

• Development of proprietary discovery engine for monoclonal antibodies and fusion proteins targeting IGFBP3/TMEM219 pathway.

• Ent001 identified as lead clinical candidate for Type 1 Diabetes and Inflammatory Bowel Disease.

First-in-class biologics for underserved autoimmune conditions, with a focus on disease-modifying treatments for Type 1 Diabetes and Inflammatory Bowel Disease.

• Ent001

  Lead clinical candidate, a first-in-class biologic with potential to preserve and restore endogenous pancreatic beta cells in T1D and original intestine structure in IBD.

• Monoclonal antibodies (mAbs)

  Selective inhibitors targeting the IGFBP3/TMEM219 pathway, generated by Enthera's proprietary discovery engine.

• Fusion proteins

  Therapeutic proteins targeting the IGFBP3/TMEM219 pathway, part of Enthera's pipeline.

1. 1Enthera – First-in-class therapeutics for auto-immune disordersentherapharmaceuticals.com
2. 2About Us – Entheraentherapharmaceuticals.com
3. 3Team – Entheraentherapharmaceuticals.com
4. 4Investors – Entheraentherapharmaceuticals.com
5. 5Enthera SRL (Italy) – Wikidatawikidata.org